Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755087 · ClinicalTrials.gov registry record · Phase 1
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
A Phase 1 study of Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements and Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, sponsored by Lapo Alinari.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05755087 is a Phase 1 study of Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements and Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements that is actively recruiting participants, run by Lapo Alinari. The registered enrollment target is 18 participants, below the 51-participant average among 6 other Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05755087, a Phase 1 study of Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements and Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, is actively recruiting participants, sponsored by Lapo Alinari.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG Tegavivint
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2028-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05755087
The ClinicalTrials.gov registry entry for NCT05755087 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 6 other Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trials with a reported enrollment target (65% lower). The listed sponsor is Lapo Alinari, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05755087 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05755087 about?
NCT05755087 is a clinical study titled "Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma". This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell ...
What is the current status of trial NCT05755087?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-03-06. Estimated completion is 2028-03-05.
What conditions does trial NCT05755087 study?
This clinical trial studies the following conditions: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type.
What interventions are being tested in trial NCT05755087?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Tegavivint (DRUG).
Who is sponsoring clinical trial NCT05755087?
This trial is sponsored by Lapo Alinari, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05755087 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
RECRUITING · Phase 2
-
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
RECRUITING · Phase 2
-
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
RECRUITING · Phase 2
-
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RECRUITING · Phase 2
-
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
All registered trials for this condition
Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
All registered trials for this condition
Ohio
All trials with a study site in Ohio
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.